ACADIA Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 80   

Articles published

ACAD 26.44 +0.52 (2.01%)
price chart
This Is A Good Time To Buy Acadia Pharmaceuticals (ACAD)
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) is in the process of a filing a new drug application (NDA) for Nuplazid (pimavanserin), which is a first-in-class treatment for Parkinson's disease psychosis, or PDP.
Related articles »  
Trader's Watch List: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), SunEdison ...
ACADIA Pharmaceuticals (NASDAQ:ACAD) CEO Uli Hacksell sold 30,000 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, October 8th.
Biotech Stocks Technical Insight - Incyte, Regado Biosciences, ACADIA Pharma ...
ACADIA Pharmaceuticals Inc.'s stock declined 4.17% to end Thursday's session at $25.71. The stock recorded a trading volume of 1.29 million shares, above its three months average volume of 1.18 million shares.
Related articles »  
Acadia Still Offers Considerable Upside Potential (ACAD)
We initially recommended the shares of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), on July 28, 2013. At that time, we noted that the stock would probably require more patience than is typical of the Event Driven Special Situations that we usually ...
Notable Movers-Eldorado Gold Corp (USA)(NYSE:EGO),ACADIA ...
ACADIA Pharmaceuticals Inc.(NASDAQ:ACAD) declared that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to NUPLAZID´┐Ż (pimavanserin) for the treatment of Parkinson's disease psychosis.
Related articles »  
News Round Up- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Cubist ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) recently declared that the U.S. Food and Drug Administration have granted Breakthrough Therapy designation to NUPLAZID for the treatment of Parkinson's disease psychosis.
Related articles »  
ACADIA Pharmaceuticals CEO Sells $724500 in Stock (ACAD)
Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) traded down 3.15% on Friday, hitting $23.40. 951,429 shares of the company's stock traded hands. ACADIA Pharmaceuticals has a one year low of $15.64 and a one year high of $32.00. The stock's ...
Related articles »  
Insider Selling: Uli Hacksell Unloads 30000 Shares of ACADIA Pharmaceuticals ...
Analysts expect that ACADIA Pharmaceuticals will post $-0.86 EPS for the current fiscal year. ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related ...
Related articles »  
Notable Updates : BioMarin Pharma , ACADIA Pharma ,Windstream Holdings ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) : Announced that a Paragraph IV Certification Notice Letter was submitted to the FDA in connection with an Abbreviated New Drug Application to the FDA for approval to market a generic version of Kuvan ...
Related articles »  
ACADIA Pharmaceuticals Director Sells 9190 Shares (ACAD)
The company reported ($0.22) earnings per share for the quarter, missing the analysts' consensus estimate of ($0.17) by $0.05.
Market Movers: Epizyme (NASDAQ:EPZM), ACADIA Pharmaceuticals Inc ...  Markets Insider
Related articles »